A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Trial Profile

A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Navarixin (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 27 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top